Stories

» Go to news main

Radiopharmacy course April 21

Posted by James Clarke on March 23, 2016 in Nuclear Medicine
Radiopharmacy course
Radiopharmacy course

Radiopharmacy course schedule

0700-0900

REGISTRATION (Breakfast on your own)

Commonwealth Foyer

0800-1800

RADIOPHARMACY COURSE

 

Commonwealth B

0800-0900              Introduction to Radiopharmacy
Doug Abrams & Mihaela Ginj
Objectives:
Upon completion of this lecture participants should be able to understand the role of radiopharmacy in nuclear medicine and the organization of a hospital radiopharmacy. Upon completion of this lecture participants should acquire a working knowledge of the regulatory requirements governing the operations of a radiopharmacy. Upon completion of this lecture participants should understand the principles of various quality control procedures employed for radiopharmaceutical testing.

0900-0945              GMP for RP Manufacturing
Kathy Seifert
Objectives: The participant will gain an understanding of the concept of Good Manufacturing Practices. The participant will be able to apply the concept of Good Manufacturing Practices to radiopharmaceuticals. The Participant will be able to identify the regulatory agency which requires GMP for radiopharmaceuticals.

0945-1000              Break


1000-1100              Radiopharmaceutical Isotope Production
Kennedy Mang’era
Objectives: At the end of the session, participants will be able to identify the various production technologies that provide commonly used SPECT diagnostic and therapeutic radioisotopes and describe challenges to future isotope supply. At the end of the session, participants will be able to explain the current supply-chain and practice initiatives for mitigating impact on diagnostic nuclear medicine during isotope shortages. At the end of the session, participants will be able to describe the status of major national technological initiatives for alternative (non-uranium) production of medical isotopes.

1100-1145              PER Production and QC – Part 1
John Wilson
Objectives: Practical aspects of PER labeling. Circumventing problems by design to simplify purification and enhance specific activity. Current developments to produce sufficient quantities of (non FDG) PERs for export.


1145-1245              Luncheon

1245-1330              PER Production and QC – Part 2
John Wilson

As of March 7, 2016

Objectives: Practical aspects of PER labeling. Circumventing problems by design to simplify purification and enhance specific activity. Current developments to produce sufficient quantities of (non FDG) PERs for export.


1330-1415              Technetium Radiopharmacy – Part 1
Kennedy Mang’era/Doug Abrams
Objectives:
At the end of the session, participants will be able to review isotope generator kinetics, review the chemistry of preparation, and quality control procedures for key SPECT radiopharmaceuticals. At the end of the session, participants
will be able to relate key SPECT radiopharmaceuticals to clinical usage and pharmacology. At the end of the session, participants will be able to identify and explain the key regulatory jurisdictions and requirements that apply to radiopharmaceutical products, operations and facilities.

1415-1430              Break


1430-1515              Technetium Radiopharmacy – Part 2
Kennedy Mang’era/Doug Abrams
Objectives:
At the end of the session, participants will be able to review isotope generator kinetics, review the chemistry of preparation, and quality control procedures for key SPECT radiopharmaceuticals. At the end of the session, participants
will be able to relate key SPECT radiopharmaceuticals to clinical usage and pharmacology. At the end of the session, participants will be able to identify and explain the key regulatory jurisdictions and requirements that apply to radiopharmaceutical products, operations and facilities.

1515-1545              Cell Labelling
Mihaela Ginj
Objectives: Upon completion of this lecture participants will be able to discuss the methods and mechanisms by which human white blood cells and platelets are radiolabelled with Tc99m or In111. Upon completion of this lecture participants will be able to discuss the methods and mechanisms by which human red blood cells are radiolabelled with Tc99m. Upon completion of this lecture participants should be able to review the advantages and disadvantages of each autologous cells radiolabelling method.

1545-1600              Break


1600-1645              Radiopharmaceutical Therapies Available in Canada
Pamela Zabel
Objectives: Recognize properties of an "ideal" therapeutic radiopharmaceutical. Review therapeutic radiopharmaceuticals available in Canada including I-131, Y-90 Theraspheres, Radium-223, Sr-89, Lu-177
DOTATATE, I-131 MIBG. Understand that health economic analysis, multi- disciplinary teamwork & collaboration may impact clinical availability and funding.


1645-1730              Miscellaneous Radiopharmaceuticals (Gallium, Octreotide, etc.)
Mihaela Ginj
Objectives: Upon completion of this lecture participants should be able to describe the basic pharmacokinetics, elimination and biodistribution for all the radiopharmaceuticals discussed. Upon completion of this lecture participants should be able to list the clinical indications for all the radiopharmaceuticals presented. Upon completion of this lecture participants should gain a working knowledge of the preparation techniques for the tracers discussed.

1730-1800              Radiopharmaceuticals in Commercial Phase III or IV Trials
Pamela Zabel
Objectives: Recognize the impact of Phase III/IV trials within the development timeline of new radiopharmaceuticals. Review some radiopharmaceuticals undergoing North American commercial Phase III or IV trials including: F-18
Amyloid agents, I-123 ioflupane (DATSCAN), Lymphoseek, F-18 Flurpiridaz, I-
123 MIBG (Adreview). Understand the need to collaborate and gather "impact on patient management/outcome" data for ultimate provincial funding.


Comments

All comments require a name and email address. You may also choose to log-in using your preferred social network or register with Disqus, the software we use for our commenting system. Join the conversation, but keep it clean, stay on the topic and be brief. Read comments policy.

comments powered by Disqus